INTRODUCTION {#s1}
============

AMP-activated protein kinase (AMPK) is a highly conserved serine/threonine protein kinase consisting of a catalytic subunit (α) and two regulatory subunits (β and γ) and is expressed in a number of tissues, including liver and skeletal muscle \[[@R1]\]. The α-subunit of AMPK contains a conserved threonine residue (Thr172) by which phosphorylation by upstream protein kinases results in AMPK activation. Kinases that can activate AMPK include liver kinase B1 (LKB1), calcium/calmodulin-dependent protein kinase (CaMKK) \[[@R2]\] and transforming growth factor β (TGF-β)-activated kinase (TAK1) \[[@R3]\]. Individuals with Peutz-Jeghers syndrome that have germline mutations in LKB1 have a higher prevalence of cancer \[[@R2]\]. AMPK can also be activated by extracellular changes, such as, depletion of ATP, low glucose, and changes of NADPH levels \[[@R4]\]. Administration of drugs and certain naturally occurring compounds can also activate AMPK. Metformin and some non-steroidal anti-inflammatory drugs (NSAIDs) can activate AMPK \[[@R5], [@R6]\]. Polyphenols (resveratrol) \[[@R7]-[@R9]\], Flavonoids (quercetin) \[[@R10]\], and Chinese herbal compounds (berberine) \[[@R11]-[@R13]\] have also been shown to activate AMPK. AMPK activation by NSAID\'s and other anti-inflammatory agents has implicated a potential role of AMPK during inflammation. Once activated AMPK can influence many effectors proteins involved in various regulatory processes that contribute to the pathogenesis of cancer. In relation to cancer metabolism mammalian target of Rapamycin (mTOR) is an important AMPK target with many efforts being made to target it in the clinic \[[@R14]\]. AMPK can also regulate p53 \[[@R15]\] and modulate the activity of transcription factors and co-regulators that control the cell cycle \[[@R16]-[@R18]\]. The current evidence suggests that AMPK can act as a tumor suppressor by modulating inflammation, opposing metabolic changes that occur during tumorigenesis and directly inducing cell-cycle arrest \[[@R19]\]. This review will provide an overview of AMPK role as a tumor suppressor and its therapeutic potential for the prevention and treatment of cancer.

AMPK: state of the art {#s1_1}
----------------------

AMPK was first described because of its role in lipid metabolism and regulating cholesterol and fatty acid levels \[[@R20], [@R21]\]. Since then the role of AMPK in regulating cellular energy homeostasis places this enzyme as a major regulator of energy metabolism. Generally speaking AMPK is activated when cellular energy is altered. A number of stresses can activate AMPK, including glucose deprivation, ischemia, hypoxia and oxidative stress \[[@R22]\]. Once activated AMPK phosphorylates numerous metabolic enzymes acutely inhibiting pathways that consume ATP and activating pathways that generate ATP, such as, glucose uptake and fatty acid oxidation \[[@R23], [@R24]\]. AMPK\'s role in regulating metabolism is well understood; predominately studied in the context of type-2 diabetes and metabolic syndrome. Li et al. 2013 describes a series of experiments elucidating the role of AMPK activation in treating diabetes. Treating primary hepatocytes with an AMPK activator known as C24 resulted in an inhibition of glucose production by down regulation of phosphoenol pyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), known genes involved in gluconeogenesis that correlated with a decrease in triglyceride and cholesterol levels. When C24 was administered to diabetic mice (db/db) it alleviated symptoms associated with diabetes, lowering blood glucose, cholesterol and circulating free fatty acids \[[@R25]\]. AMPK activation can prevent atherosclerosis and reperfusion injury of the heart in experimental animals \[[@R26], [@R27]\]. Conversely, dysregulation of AMPK activation has been found to be associated with the risk of developing insulin resistance (IR) and metabolic syndrome--associated diseases in both experimental animal models and in clinical studies \[[@R28]\]. AMPK inhibits essentially all anabolic pathways that promote cell growth including fatty acids, phospholipids, protein and ribosomal RNA synthesis \[[@R1], [@R24]\]; thus, in cancer where the energy demands of the cell are elevated due to rapid growth and division AMPK activators may be a suitable therapeutic intervention for treating cancer.

Relevance of AMPK to cancer {#s1_2}
---------------------------

Deregulating cellular energetics is a core hallmark of cancer \[[@R29]-[@R31]\]. AMPK activation may act as a metabolic tumor suppressor by regulating energy levels, enforcing metabolic checkpoints and inhibiting cell growth. There is a vast literature demonstrating the tumor suppressor function of AMPK in lung, colorectal, and liver cancer with a growing literature in other cancers, such as, prostate and melanoma.

### AMPK and lung cancer {#s1_2_1}

Non-small-cell lung cancer (NSCLC) is the most common lung cancer type, accounting for 75-80 percent of all lung cancer cases \[[@R32]\]. It is estimated that 30-50 percent of NSCLC have mutations in the gene coding for LKB1 \[[@R33], [@R34]\]. It is hypothesized that mutations in LKB1 result in unsuppressed cell proliferation due to the inability to activate AMPK in response to the tumor \[[@R35]\]. William et al. isolated tumors from patients with NSCLC and found that AMPK activation correlated with a better prognosis and a significant increase in overall survival \[[@R32]\]. Furthermore, AMPK activity was significantly higher in lung tumors obtained from never smokers than in smokers. Similar results were seen in a study investigating the correlation of LKB1 mutations with several clinicopathological characteristics of 155 patients with lung adenocarcinoma that found LKB1 mutations associated with smokers and not nonsmokers \[[@R36]\]. Specific AMPK activators may be useful in treating NSCLC patients with LKB1 mutations and history of smoking.

### AMPK and colorectal cancer {#s1_2_2}

Colorectal cancer (CRC) is the third leading cause of cancer-related mortality in the U.S. with no effective therapy for advanced colorectal carcinoma \[[@R37]\]. Colorectal cancer has a strong inflammatory and metabolic component suggesting AMPK activation may be useful in colorectal cancer management. The direct relationship between AMPK activation and colon cancer survival has yet to be established. A recent study with several hundred colorectal cancer samples was unable to find a correlation between overall survival and AMPK activation. However, the study was able to demonstrate that AMP activation correlated with mitogen activated protein kinase (MAPK) activation and within that particular subset, AMPK activation was associated with a significant decrease in cancer-specific mortality \[[@R38]\]. Several reports have demonstrated that activating AMPK by 5-aminoimidazole-4-carboxamide-ribonucleoside (AICAR) or phenformin in human cancer cells results in apoptosis by several mechanisms, including modulating the MAPK pathway \[[@R39], [@R40]\]. Taken together, these findings suggest AMPK activation may be beneficial in regulating cell survival in colorectal cancer tumor types.

### AMPK and liver cancer {#s1_2_3}

The most common type of liver cancer is hepatocellular carcinoma (HCC), which is the fourth most commonly diagnosed cancer in the U.S. \[[@R41]\]. The link between AMPK and normal liver function is very evident due to the important role of the liver in regulating fatty acid oxidation and lipid metabolism. Diseases of the liver including HCC are often associated with metabolic disorder \[[@R42]\]. Loss of LKB1 and AMPK expression correlates with a poor prognosis. In patient samples collected prior to hepatectomy, low LKB1 expression correlated with a greater degree of tumor severity and significantly shorter disease-free survival \[[@R43]\]. Similarly, decreased AMPK activity in patient tumors correlated with an aggressive clinical phenotype and poor prognosis \[[@R44]\]. It appears that the LKB1-AMPK pathway directly influences proliferation of HCC cells \[[@R45]\]. *In vitro* knockdown of AMPK in HCC cells resulted in greater tumorigenicity when implanted into nude mice \[[@R11]\]. While the mechanisms are still under investigation, AMPK activation appears to attenuate HCC by inducing cell senescence \[[@R46]\] and autophagy \[[@R47]\].

### Role of AMPK in other cancers {#s1_2_4}

More recently, pre-clinical studies have shown AMPK having some involvement in others cancers, including melanoma \[[@R11], [@R48]-[@R52]\], breast cancer \[[@R53]-[@R56]\], prostate cancer \[[@R57], [@R58]\], ovarian cancer \[[@R59], [@R60]\] and leukemia\'s \[[@R61]\]. In melanoma, AMPK was found to be an important regulator for the maintenance of MITF (Microphthalmia-associated transcription factor), a protein important for normal melanocyte development and differentiation that is associated with melanoma progression \[[@R50]\]. AMPK activation has also been shown to inhibit the metastatic potential of melanoma cells through a reduction in the activity of the ERK signaling pathway and COX-2 protein levels \[[@R11]\] and by inducing autophagic cell death and apoptosis through AMPK/JNK signaling \[[@R51]\]. In primary breast cancer, AMPK activity is diminished in an estimated 90% of cases \[[@R62]\]. Fox et al. demonstrated that reintroducing AMPKα2 suppressed the growth of MCF-7 breast cancer cells \[[@R55]\]; whereas, in a different study overexpressing a constitutively active form of AMPK reduced cell death induced by low glucose \[[@R56]\]. In Chronic Myeloid Leukemia (CML), BCL-ABL transformed cells exhibit overly expressed mTOR activity by which activating AMPK may provide therapeutic advantages \[[@R61]\]. Based on the evidence, AMPK does exhibit tumor suppressor-like activation in certain primary cancers; however, there are some tumors and cellular contexts in which the proposed role may not be applicable and more investigation is warranted.

Cancer Related Targets of AMPK {#s1_3}
------------------------------

### mTOR {#s1_3_1}

Mammalian target of Rapamycin (mTOR) is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription \[[@R63]\]. mTOR forms two functionally distinct complexes, mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 2). AMPK inhibits mTOR through the phosphorylation of tuberous sclerosis complex protein-2 (TSC2), which converts the small G protein Rheb to its inactive GDP form and the phosphorylation of Regulatory associated protein of mTOR(Raptor) proteins that ultimately leads to inhibition of downstream targets p70s6kinase and activation of 4EBP, which are directly involved in translation and protein synthesis \[[@R64]\]. The activated TSC1/TSC2 complex regulates the activity of mTORC1 and raptor, which controls cell growth mainly through the regulation of protein translation. The AMPK-mTOR axis can also regulate autophagy, a catabolic degradation process within the cell. Activation of autophagy can lead to tumor growth by maintaining energy production and offers another therapeutic advantage of AMPK activation \[[@R65]\]. Inhibition of mTORC1 is sufficient to induce autophagy in the presence of nutrients in yeast or mammalian cells, establishing mTORC1 as a conserved and critical repressor of autophagy \[[@R66]\]. AMPK regulates several metabolic processes and activates the TSC to repress mTORC1 under conditions of energy stress. AMPK also directly regulates autophagy by phosphorylating and activating UNC-51-like kinase1 (ULK1) at Ser317, a key initiator of autophagy that is negatively regulated by the mTOR kinase \[[@R67]-[@R69]\]. Concomitant with suppression of mTORC1 autophagy is induced accompanied by loss of cell viability \[[@R70]\].

### COX-2 {#s1_3_2}

Cyclooxygenase-2 (COX-2) is a known pro-inflammatory enzyme that has been shown to be up regulated in a number of cancers and correlates with tumorigenesis \[[@R71], [@R72]\]. COX-2 is responsible for the formation of important pro-inflammatory mediators, including prostanoids, which have been shown to promote tumor growth in a variety of cancers \[[@R73], [@R74]\]. While there is limited evidence demonstrating a direct link, several studies were able to show a correlation between AMPK activation by numerous agents and COX-2 inhibition in colorectal cancer cell lines and xenografts \[[@R75], [@R76]\], as well as, leukemic \[[@R77]\] and melanoma cell lines \[[@R11]\]. While there are several COX-2 inhibitors available in the clinic the use of these selective COX-2 inhibitors are limited by their side effects \[[@R78], [@R79]\]. Thus, activating AMPK may provide a novel approach to inhibiting COX-2 at sites of inflammation, such as, within the tumor microenvironment.

### p53 {#s1_3_3}

p53 is a tumor suppressor that plays an important role in preventing tumor development by responding to a number of cellular stresses, including DNA damage, oncogene activation and hypoxia and inducing cell cycle arrest or senescence \[[@R80], [@R81]\]. It is estimated that p53 is inactivated in approximately 50 percent of human cancers \[[@R82]\]. Many kinases stabilize p53 by phosphorylation under conditions of metabolic stress. AMPK can directly phosphorylate p53 leading to its stabilization and transcriptional activity \[[@R15]\] and promote p53 gene expression \[[@R83]\]. In fact, in a study utilizing murine embryonic fibroblast the absence of AMPKα2 tumors exhibited decreased p53 expression and enhanced cell growth and transformation \[[@R84]\]. Under low-energy status AMPK activation maintains energy homeostasis for normal cellular events and also induces p53 to restrict cell growth rates to save more energy to limit induction of potential damage in energy-rich environments. A recent study revealed a prosurvival role for p53 in cells metabolically impaired by glucose limitation \[[@R15]\]. Activation of p53 allows cells to respond to glucose deprivation by arresting their proliferation until glucose is restored. The ability of glucose deprivation to induce p53 was found to be AMPK dependent. Although loss of p53 confers a selective growth advantage to cancer cells, loss of p53 impairs the ability of cancer cells to respond to metabolic changes induced by metformin or AICAR and to survive under conditions of nutrient deprivation \[[@R85]\]. Metformin can also inhibit cancer cell proliferation in p53 deficient cells \[[@R86]\].

### Acetyl-CoA carboxylase (ACC) {#s1_3_4}

Acetyl-CoA carboxylase (ACC) is a well-established downstream target of AMPK involved in lipid metabolism \[[@R87]\]. ACC catalyzes acetyl-CoA carboxylation to produce malonyl-CoA a substrate for fatty acid biosynthesis and inhibitor of fatty acid uptake \[[@R88]-[@R90]\]. In several cancers, tumor progression is accompanied by marked changes in the expression of enzymes involved in fatty acid homeostasis, including ACC. In several cases, cancer cell proliferation and survival are dependent on ACC activity and inhibiting ACC results in apoptosis \[[@R91], [@R92]\].

### Akt {#s1_3_5}

The signaling relationship between Akt and AMPK is quite complex. On one hand, Akt has been shown to be a negative regulator of AMPK and upstream positive regulator of mTOR. Both pathways involve direct phosphorylation of TSC2, a negative regulator of mTOR. AMPK activates TSC2 and Akt inhibits TSC2 both leading to mTOR activation and subsequent increase in protein synthesis and other cellular processes. The negative regulation of AMPK by Akt involves the regulation of cellular ATP levels. In cells with activated Akt there is depleted ATP and decline in AMPK activity \[[@R93]\]. On the other hand other studies have shown that activated AMPK can also induce Akt phosphorylation and activation \[[@R94], [@R95]\]. To further complicate matters in some circumstances activating AMPK can inhibit Akt signaling. When cancer cells are treated with AICAR, a widely used AMP-Kinase activator, it resulted in S-phase growth arrest in an LKB1-independent fashion by inducing p53 and inhibiting Akt phosphorylation \[[@R96]\]. Thus, the cross talk between AMPK and Akt is bidirectional, yet the functional consequence in terms of tumor progression is unclear. Choudhury et al. using various prostate cancer cell lines was able to illustrate this bidirectional feedback mechanism. Treating androgen-independent PC3 and PC3M cells with AICAR, an AMPK activator depending on dose or time either activated or inhibited Akt; however, in both cases mTOR activity and tumor progression was inhibited, which was found to be independent of PI3K-Akt signaling \[[@R97]\]. Taken together, depending on the circumstances activating AMPK may inhibit or promote Akt signaling; however, the phenotypic consequences that follow may be dependent on the tumor and cellular context. Further investigation and careful consideration of the feedback mechanism between AMPK and PI3K will be needed when \[[@R94], [@R95]\] targeting AMPK for cancer treatment.

How AMPK modulates inflammation {#s1_4}
-------------------------------

The link between inflammation and cancer has been well established; however, the mechanism by which AMPK control on metabolism can directly influence inflammation and tumorigenesis is still unclear. The most intuitive relationship is that immune cells like most cells have energy demands, especially during inflammatory pathologies, including diabetes and cancer. It is now becoming evident that unstimulated or naive immune cells, including dendritic cells, neutrophils, macrophages and T-cells utilize mainly oxidative metabolism, including fatty acid oxidation to generate ATP. However, when activated by pro-inflammatory cytokines, binding of ligands to TLRs (Toll-like receptors), or antigen presentation the immune cells switch to the use of aerobic glycolysis instead \[[@R98]\]. Since AMPK is important regulator of these metabolic processes it is possible that AMP-activating drugs can modulate inflammation. Indeed, Carroll, et al. found that AMPKα1-deficient macrophages and DCs exhibit heightened inflammatory function and an enhanced capacity for antigen presentation favoring the promotion of Th1 and Th17 responses. Th1 and Th17 responses play a complex and controversial role in tumor immunity either promoting or suppressing tumor growth. A second study, revealed that Macrophages and DCs generated from AMPKα1-deficient mice produced higher levels of pro-inflammatory cytokines and decreased production of the anti-inflammatory cytokine IL-10 when activated compared with WT cells \[[@R99]\]. Pro-inflammatory cytokines have been correlated with tumor progression in various cancers. Lung cancer is highly inflammatory and managing the inflammation has been shown to inhibit tumorigenesis. Hoogendijk, et al. found that activation of AMPK *in vitro* reduced cytokine production in the alveolar macrophage cell line MH-S. *In vivo*, AMPK activation inhibited lung inflammation by reducing Lipoteichoic acid-induced neutrophil influx and by altering cytokine/chemokine levels in the bronchoalveolar space \[[@R100]\]. Inflammation is a one of the classic hallmarks of cancer and targeting AMPK is this context may beneficial for cancer treatment.

Targeting AMPK for Cancer Prevention and Treatment {#s1_5}
--------------------------------------------------

### Metformin {#s1_5_1}

Metformin is a drug used to decrease hyperglycemia in patients with type-2 diabetes, in part by activating AMPK and is currently under investigation as a potential treatment for several types of cancer \[[@R101], [@R102]\]. Epidemiological and clinical data suggest a benefit of metformin treatment in preventing certain cancers \[[@R103]-[@R106]\]; however, the molecular mechanisms are incompletely understood. Recent preclinical studies were able to demonstrate metformin efficacy in various cancer types. In NSCLC cell lines metformin inhibited proliferation and made the cells more sensitive to growth ionizing radiation \[[@R107]\] and *in vivo* metformin was found to prevent tobacco carcinogen-induced lung tumorigenesis \[[@R108]\]. Similarly, metformin significantly increased the radiosensitivity of luminal-type MCF-7 breast cancer cells \[[@R101]\]. Metformin abolished the self-renewal capabilities and induced apoptosis in HCC cell lines \[[@R109]\] and low dose metformin inhibited adipocyte-dependent proliferation in ID8 mouse ovarian cancer cell lines \[[@R102]\]. Metformin was also shown to significantly reduce aberrant crypt foci, the precursors to colon polyps with a modest reduction in polyp formation in animals treated with chemical carcinogen Azoxymethane \[[@R110]\]. In melanoma, metformin inhibits invasion and metastasis development through AMPK/p53 axis activation \[[@R49]\]. While there remains uncertainty regarding whether or not AMPK activation is required for metformin benefits \[[@R111]\] it still remains clear that metformin can activate AMPK and may be useful in the prevention and treatment of cancer.

### Non-steroidal anti-inflammatory drugs (NSAIDs) {#s1_5_2}

Inflammation has been shown to play a critical role in tumor initiation, progression, and metastasis \[[@R112]\]. Aspirin, a non-steroidal anti-inflammatory drug (NSAID) has been shown to correlate with a decreased risk of developing cancer, particularly preventing colorectal cancer (CRC) \[[@R113], [@R114]\]. The majority of the studies are observational in nature and the mechanisms are currently being investigated; however, it is believed that aspirin may prevent CRC by inhibiting COX-2 \[[@R115]\]. This ultimately led to the development of a new class of NSAIDs that are more selective for COX-2 inhibition for use as chemopreventive agents. Interestingly, aspirin and other NSAIDs have also been shown to activate AMPK. When colorectal cancer cells were treated with aspirin, there was a significant increase in AMPK activation and inhibition of downstream mTOR signaling \[[@R116]\]. Aspirin use has also been shown to correlate with the prevention of several other cancers including lung, liver and ovarian; however, the molecular mechanisms involving its prevention remains enigmatic. It is likely that once aspirin or other NSAIDs activate AMPK there is regulation of other inflammatory regulatory pathways. For example in the lung, AMPK activation can alleviate inflammation that results from injury or infection by directly modulating the activity of macrophages, neutrophils and T cells \[[@R99], [@R100], [@R117]\]. Leukocytes and their cytokines play important regulatory roles in all aspects of tumor development; therefore the anti-inflammation drugs targeting AMPK activation may play a more meaningful role for the treatment of cancer-associated inflammation.

### Natural products {#s1_5_3}

The use of natural products as chemopreventive agents has increased worldwide because of their potential low toxicity and effectiveness \[[@R118]\]. Observational studies have suggested the efficacy of some natural products in preventing the development of cancer; however, clinical trials have yet to be conducted in most cases to support this notion. In preclinical studies, several classes of natural products have been shown to target many mediators that play important roles in cancer, including AMPK (Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). Flavones, such as wogonin \[[@R119]\], tanshinone IIA \[[@R120]\], quercetin \[[@R121], [@R122]\] and cryptotanshinone \[[@R123]\] induce AMPK activation inhibiting proliferation and inducing apoptosis in various types of cancer cells. Polyphenols are also an abundant source of AMPK activators. Resveratrol induces autophagy in chronic myelogenous leukemia cells by regulating the AMPK/mTOR pathway \[[@R124]\]. In colorectal cancer cells, magnolol \[[@R125]\], epigallocatechin-3-gallate (EGCG) \[[@R126]\], and widdrol \[[@R127]\] could induce apoptosis, inhibit migration, and prevent invasion by AMPK-dependent mechanisms. In breast cancer cells, nordihydroguaiaretic acid inhibits mTORC1 activity through disruption of mTOR-Raptor complex and AMPK activation \[[@R128]\], while demethoxycurcumin, a potent AMPK activator has broad spectrum anticancer activity in triple-negative breast cancer cells \[[@R129]\] with the parent compound curcumin exerting similar effects in ovarian cancer cells \[[@R130]\] and in colorectal cancer cells by AMPK-p53 activation \[[@R131], [@R132]\]. Antroquinonol, extracted from *antrodiacamphorate* displays anti-cancer activity against HCC cells through an AMPK-dependent manner \[[@R133]\] and honokiol, has been shown to inhibit proliferation in several cancer cell types, also through AMPK dependent mechanisms \[[@R134]\]. Berberine has been shown to inhibit colon tumor formation in AOM/DSS mouse model through activation of AMPK \[[@R135]\]. Berberine \[[@R11]\]or Ginsenoside 20-O-b-D-Glucopyranosyl-20(S)-Protopanaxadiol \[[@R48]\] inhibit melanoma cell growth and invasion through the activation of AMPK *in vitro* \[[@R11], [@R48]-[@R52]\]. Thus, these agents may serve as AMPK activators and provide a crucial link between natural products and the prevention and treatment of cancer.

![AMPK is a tumor suppressor for cancer prevention and treatment\
NSAIDs, Natural products, TCM and metformin can all activate AMPK. AMPK negatively regulates the mTOR signal pathway, resulting in inhibition of cancer proliferation and growth. Activated AMPK negatively regulates COX-2, a pro-inflammatory enzyme associated with tumorigenesis. AMPK can induce phosphorylation of tumor suppressor p53, resulting in cell cycle arrest. Activation of AMPK can also induce phosphorylation of ACC influencing lipid metabolism. Interactions leading to activation of molecular targets are indicated by arrows; those inhibited are indicated by a bar. Activation of AMPK can modulate multiple pathways leading to anticancer activities. TCM=Traditional Chinese Medicine; NSAIDs=Non-steroidal anti-inflammatory drugs.](oncotarget-06-7365-g001){#F1}

###### Natural products extracted from herbal medicines that can activate AMPK to inhibit the growth of multiple cancer types

  Natural products                                            Effect of AMPK activation                                              Cancer type                 References
  ----------------------------------------------------------- ---------------------------------------------------------------------- --------------------------- ----------------------
  Berberine                                                   Inhibition metastasis by AMPK/ERK                                      Melanoma                    \[[@R11]\]
  Ginsenoside 20-O-b-D-Glucopyranosyl-20(S)-Protopanaxadiol   Induces autophagic cell death by AMPK/JNK                              Melanoma                    \[[@R48]\]
  Wogonin                                                     Inhibition translation by AMPK/mTOR/4EBP1                              Glioblastoma                \[[@R119]\]
                                                                                                                                                                 
  Tanshinone IIA                                              Induces autophagic cell death by AMPK/mTOR/p70S6kinase                 Leukemia                    \[[@R120]\]
  Quercetin                                                   Growth inhibition through AMPK/COX-2                                   Breast and colon cancer     \[[@R121], [@R122]\]
  Cryptotanshinone                                            Induce autophagic cell death by AMPK/mTOR                              Hepatoma and colon cancer   \[[@R123]\]
  Resveratrol                                                 Triggered autophagic cell death via AMPK/mTORC2/p62                    Leukemia                    \[[@R124]\]
  Magnolol                                                    Induce apoptosis of colon cancer by AMPK/p53                           Colon cancer                \[[@R125]\]
  Epigallocatechin-3-gallate                                  Suppress colon cancer proliferation by ROS/AMPK/COX-2                  Colon cancer                \[[@R126]\]
  Widdrol                                                     Induction of apoptosis via AMPK                                        Colon cancer                \[[@R127]\]
  Nordihydroguaiaretic acid                                   Inhibition breast cancer growth by AMPK/mTORC1                         Breast cancer               \[[@R128]\]
  Demethoxycurcumin                                           Inhibition breast cell growth by AMPK/mTORC1                           Breast cancer               \[[@R129]\]
  Curcumin                                                    Suppress proliferation by AMPK/p53                                     Ovarian cancer              \[[@R130], [@R131]\]
  Antroquinonol                                               Anticancer by AMPK/mTOR/p70s6kinase and 4EBP1                          Hepatocellular carcinoma    \[[@R133]\]
  Honokiol                                                    Inhibition invasion and migration of breast cancer by LKB1/AMPK/mTOR   Breast cancer               \[[@R134]\]
  Berberine                                                   Inhibition growth by AMPK/mTOR and AMPK/COX-2                          Colon cancer                \[[@R135]\]

### AICAR {#s1_5_4}

5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) is the pharmacologic activator of AMPK. AICAR is transported in the cell by the adenosine transporter and is metabolized to an AMP analog, ZMP, which in turn binds to the γ-subunit of AMPK, thus enabling the activating phosphorylation of AMPK by LKB1 on Thr172 \[[@R136]\]. AICAR mediated AMPK activation has been reported to inhibit cell proliferation and cell cycle progression via inhibition of the PI3K/Akt pathway and the cell cycle regulatory proteins p21, p27 and p53 \[[@R96]\]. AICAR-mediated AMPK activation was found to be a proficient cytotoxic agent in Acute lymphoblastic leukemia (ALL) cells and the mechanism of its anti-proliferative and apoptotic effect appear to be mediated via activation of p38-MAPK pathway, increased expression of cell cycle inhibitory proteins p27 and p53, and downstream effects on the mTOR pathway, hence exhibiting therapeutic potential as a molecular target for the treatment of childhood ALL \[[@R137]\]. In human colorectal cancer cells AICAR through AMPK signaling pathway sensitizes death receptor-mediated cytotoxicity \[[@R138]\]. These findings suggest that AICAR can be used alone or combined with chemotherapies for cancer treatment.

### Traditional Chinese medicine {#s1_5_5}

The use of traditional Chinese medicine (TCM) for cancer prevention and treatment has stimulated much interest in recent years \[[@R139]\]. TCM integrates a wide range of herbal medicines often used in combinations of more than four single herbal medicines. The use of TCM in treating metabolic disorders has been well established. There are at least twenty medicinal herbs in TCM used for the treatment of metabolic disorders that involve some regulation of mitochondrial function, stimulation of glycolysis and AMPK activation \[[@R140]\]. Jiaotaiwan (JTW), composed of *Coptischinensis* (CC) is one of the most widely used agents for treating diabetes and the mechanism of action involves AMPK activation in the liver and increased glucose uptake \[[@R141]\]. Hugan Qingzhi tablet (HQT), a lipid-lowering traditional Chinese medicine formula has been shown to exert a preventive effect against hepatic steatosis and its mechanism of action may involve activation of AMPK and PPARα pathways \[[@R142]\]. Activation of AMPK by TCM agents has produced similar results seen with metformin. Thus, many herbal medications used in traditional Chinese medicine to treat chronic inflammation and diabetes, are potential candidates for targeting AMPK for prevention and treatment of cancer.

The potential drawbacks of activation of AMPK {#s1_6}
---------------------------------------------

While targeting AMPK has become an attractive target for cancer therapy there are cases in which AMPK activation may promote cancer. In the case of mTOR, isoform specificity is particularly important. Most cancers have activation in mTOR complex 1 (mTORC1), which regulates growth through effectors, such as 4EBP1 and S6K1, as discussed above. Thus, inhibiting mTORC1 will prevent cell protein synthesis and proliferation; however, inhibiting mTORC1 without inhibiting mTOR complex 2 (mTORC2) can activate PI3K-Akt signaling pathway and promote tumor survival as previously mentioned. Activation of AMPK in most cases results in mTORC1 inhibition; however, the effects on mTORC2 and Akt activation are incompletely understood. If a particular AMPK activator is to be used solely to regulate mTOR its success would depend on its capacity to inhibit both complexes. AMPK agonist in recent studies has shown to possess both tumor suppressing and tumor promoting abilities, which may result from mechanisms relating to feedback regulation \[[@R143], [@R144]\]. In the case of prostate cancer AMPK activation may be associated with poor prognosis. Ca2+/CaM-dependent protein kinase kinase β (CaMKKβ) is elevated and correlated with prostate cancer cell migration and proliferation. Recall that CaMKKβ is an upstream activator of AMPK. Inhibition of CaMKII activity by synthetic agents has been shown to suppress prostate cancer cell growth \[[@R145]\]. CaMKKβ-induced prostate cancer cell migration requires AMPK activation \[[@R58]\] and blocking CaMKK/AMPK pathway results to the inhibition of prostate cancer cell growth. It is likely that in the case of cancer treatment AMPK activation may be cell type and context dependent and will be one of the most difficult conundrums to address in future studies.

Future perspectives {#s1_7}
-------------------

A considerable amount of evidence supports the notion that AMPK activation may act as a metabolic tumor suppressor. AMPK activation, whether direct or indirect has been shown to alleviate symptoms associated with type-2 diabetes and metabolic syndrome and has been a well-established therapeutic for these particular disorders. Epidemiological studies suggest that patients prescribed metformin, a drug commonly used to treat type-2 diabetes have a lower risk of developing cancer; conversely, patients with diabetes have higher incidences of cancer. It is hypothesized that AMPK activation can oppose tumor development by reprogramming cellular metabolism targeting one of the fundamental requirements necessary for cancer to develop and progress. In several cancers loss of AMPK signaling is associated with a worse clinical outcome in lung, colon and liver cancer. Future studies would have to further delineate whether or not loss of AMPK activity increases the susceptibility to cancer, as in the case of loss of LKB1. It is plausible considering the well-established cancer-related targets that are known to be regulated by AMPK, including, p53, COX-2, ACC, and mTOR (Figure [1](#F1){ref-type="fig"}).

In our opinion, the more exciting outcomes for activating AMPK for chemoprevention will come from the area least studied in relation to AMPK and that is inflammation. Considering that AMPK is activated by NSAIDs and agents that are traditionally seen as anti-inflammatory raises an important question as to whether the chemopreventive activity of AMPK activation is related to its ability to modulate inflammation. Traditional Chinese medicine (TCM) has been used for hundreds of years to prevent and treat many maladies, including cancer. The use of TCM has been linked to low incidence of certain cancers. Interestingly, many of the herbal remedies historically used in TCM have been used to alleviate inflammation, and recent reports contribute this to the anticancer activities seen with these compounds. It is tempting to speculate that AMPK-mediated anticancer activities may be related to inflammation and contribute to the effectiveness of TCM and potentially other AMPK activators. Currently, most of the research involving AMPK involves metabolism and only recently has work begun to unravel the direct role of AMPK in inflammatory processes and how it may relate to the anti-cancer activities seen by metformin, NSAIDs, TCM and other AMPK activators. Furthermore, there are all the other indirect effects of AMPK activation that still have to be investigated. Therefore, additional studies are necessary before AMPK activators can be used for clinical use for cancer prevention and treatment.

Weidong Li and Shakir M. Saud contributed equally to this work and should be considered co-first authors. This work was partly supported by National Natural Science Foundation of China (No.81273718 and 81102587) and China Postdoctoral Science Foundation (No. 2012T50199).

**CONFLICT OF INTEREST**

The authors declare that there is no conflict of interest.

AMPK

:   AMP-activated protein kinase

CaMKK

:   calcium/calmodulin-dependent protein kinase

NSAIDs

:   non-steroidal anti-inflammatory drugs

mTOR

:   mammalian target of rapamycin

4EBP1

:   eukaryotic translation initiation factor 4E binding protein 1

NSCLC

:   Non-small-cell lung cancer

CRC

:   Colorectal cancer

HCC

:   hepatocellular carcinoma

ACC

:   acetyl-CoA carboxylase

LKB1

:   Liver Kinase B1

COX-2

:   Cyclooxygenase 2
